425 related articles for article (PubMed ID: 33026749)
1. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Kircik LH; Schlesinger TE; Tanghetti E
J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
[TBL] [Abstract][Full Text] [Related]
2. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Bagel J; Nelson E; Riley C; Hetzel A
J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
[TBL] [Abstract][Full Text] [Related]
3. Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Kircik L; Stein Gold L; Teng J; Moore A; Cantrell W; Alonso-Llamazares J; Koo J
J Drugs Dermatol; 2020 Aug; 19(8):723-732. PubMed ID: 32845591
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
5. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
Petersen B; Lebwohl M
J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
[TBL] [Abstract][Full Text] [Related]
6. Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Warren RB; Gold M; Gooderham M; Kircik LH; Lacour JP; Laws P; Liljedahl M; Lynde C; Mørch MH; Sondermann W; Thaçi D
J Drugs Dermatol; 2021 Apr; 20(4):436-441. PubMed ID: 33852252
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
8. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
[TBL] [Abstract][Full Text] [Related]
9. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
[TBL] [Abstract][Full Text] [Related]
10. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
11. The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
Ozyurekoglu E; Kircik L
J Drugs Dermatol; 2022 Apr; 21(4):381-386. PubMed ID: 35389594
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab.
Bagel J; Nelson E
J Drugs Dermatol; 2022 Mar; 21(3):235-240. PubMed ID: 35254755
[TBL] [Abstract][Full Text] [Related]
13. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
16. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
Bagel J; Zapata J; Nelson E
J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
[TBL] [Abstract][Full Text] [Related]
17. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
[TBL] [Abstract][Full Text] [Related]
19. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
Wu JJ; Veverka KA; Lu M; Armstrong AW
J Dermatolog Treat; 2019 Aug; 30(5):454-460. PubMed ID: 30307343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
